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Muzaffar H. Qazilbash1Approximately 20% of patients with multiple myeloma (MM) have renal failure at diagnosis, and about 5% are
dialysis-dependent. Many of these patients are considered ineligible for autologous hematopoietic stem cell
transplantation (auto-HSCT) because of a high risk of treatment-related toxicity. We evaluated the outcome
of 46 patient with MM and renal failure, defined as serum creatinine.2mg/dL sustained for.1month before
the start of preparative regimen. Patients received auto-HSCTat our institution between September 1997 and
September 2006. Median serum creatinine and creatinine clearance (CrCl) at auto-HSCTwere 2.9 mg/dL
(range: 2.0-12.5) and 33 mL/min (range: 8.7-63), respectively. Ten patients (21%) were dialysis-dependent.
Median follow-up in surviving patients was 34 months (range: 5-81). Complete (CR) and partial responses
(PR) after auto-HSCTwere seen in 9 (22%) and 22 (53%) of the 41 evaluable patients, with an overall response
rate of 75%. Two patients (4%) died within 100 days of auto-HSCT. Grade 2-4 nonhematologic adverse events
were seen in 18 patients (39%) and included cardiac arrythmias, pulmonary edema, and hyperbilirubinemia.
Significant improvement in renal function, defined as an increase in flomerular filtration rate (GFR) by 25%
above baseline, was seen in 15 patients (32%). Kaplan-Meier estimates of 3-year progression-free survival
(PFS) and overall survival (OS) were 36% and 64%, respectively. In conclusion, auto HSCT can be offered
to patients with MM and renal failure with acceptable toxicity and with a significant improvement in renal func-
tion in approximatelyone-thirdof the transplantedpatients. In this analysis, amelphalan (Mel) doseof 200mg/m2
was not associated with an increase in toxicity or nonrelapse (Mel) mortality (NRM).
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6/j.bbmt.2009.03.021failure in MM patients, including monoclonal light-
chain-induced proximal tubular damage, hypercalce-
mia, dehydration, infection, hyperuricemia, and the
use of nephrotoxic drugs [2]. Amyloid deposition and
plasma cell infiltration are less frequent causes for re-
nal impairment [3]. Renal failure was a predictor of
poor prognosis in early chemotherapy trials for
MM. Patients requiring dialysis were reported to
have a poorer prognosis [4]. Renal failure is also con-
sidered a marker of high tumor burden and inadequate
therapy [5].
High-dose chemotherapy (HDT) using melphalan
(Mel) 200 mg/m2 with autologous hematopoietic stem
cell transplantation (auto-HSCT) improves the out-
come of patients with MM in terms of remission rates
and survival with a nonrelapse mortality (NRM) of
\5% [6,7]. Because of concerns about higher rates of
treatment-related toxicity and NRM, patients with re-
nal insufficiency are frequently excluded from HDT
protocols [8]. A few recent reports have addressed the
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concurrent renal failure, and showed that this treat-
ment is feasible in patients with renal insufficiency,
even in a dialysis-dependent setting [8-10]. The objec-
tive of this retrospective analysis study was to evaluate
the safety and feasibility of this approach in patients
with myeloma and renal failure, who received HDT
and auto-HSCT at our institution. We also analyzed
the impact ofMel dose on the outcome, and the revers-
ibility of renal failure.PATIENTS AND METHODS
Patients
Forty-six patients withMM and concomitant renal
failure, defined as a serum creatinine $2 mg/dL sus-
tained for more than 1 month before the start of pre-
parative regimen HSCT. Patients received high-dose
melphalan followed by auto-HSCT were included in
this analysis. Patients received auto-HSCT between
April 1997 and September 2006. Ten patients (21%)
were hemodialysis-dependent. Median age at auto-
HSCTwas 55 years (range: 29-72). Forty-two patients
were\65 years old and 4 were $65 years old. Median
interval between diagnosis and transplant was 12
months (range: 5-107). All patients gave written
informed consent before auto-HSCT, which was ob-
tained in accordance with the Declaration of Helsinki.Table 1. Chronic Kidney Disease Staging*
Stage Description GFR, mL/min/1.73 m2
—† At increased risk $60 (with chronic kidney
disease risk factors)
1 Kidney damage: normal or
increased GFR
$90
2 Kidney damage, mild decrease in GFR 60-89
3 Moderately decreased GFR 30-59
4 Severely decreased GFR 15-29
5 Kidney failure <15 (or dialysis)
GFR indicates glomerular filtration rate.
*National Kidney Foundation Kidney Disease Outcomes Quality Initia-
tive Classification, Prevalence, and Action Plan for Stages of Chronic
Kidney Disease.
†Stages 1 to 5 indicate patients with chronic kidney disease; the first
row, without a stage number, indicates patients at increased risk for de-
veloping chronic kidney disease.
Chronic kidney disease is defined as either kidney damage or GFR less
than 60 mL/min per 1.73 m2 for 3 or more months.
Kidney damage is defined as pathologic abnormalities ormarkers of dam-
age, including abnormalities in blood or urine tests or imaging studies.Treatment
Peripheral blood stem cells (PBSC) weremobilized
andcollected followinggranulocyte colony-stimulating
factor (G-CSF) alone (36) or chemotherapy 1 G-CSF
(10) [11]. All 46 patients received high-dose Mel on
days 24 and 23. Thirty-three patients received a Mel
dose of 200 mg/m2, 9 patients received 180 mg/m2,
and 4 patients received 140 mg/m2 [11,12]. Patients
with older age or worse renal impairment were not
intended to receive a lower Mel dose. Before this anal-
ysis, the common practice of some attending physicians
was to use a lower mel dose for patients with impaired
renal function, a practice that was not uniform and
hence the discrepancy in doses. Unmanipulated autolo-
gous stem cells were infused 48 hours later. All patients
receivedG-CSF, 5 mg/kg/day fromday11 until the ab-
solute neutrophil count (ANC) was 0.5  109/L for 2
consecutive days, in accordance with our departmental
guidelines. Blood products were given for hemoglobin
#8 g/dL and platelets \20  109/L. Hemodialysis
was administered as indicated in dialysis-dependent
patients. Mucositis prophylaxis included standard
mouth care and prophylactic antimicrobial agents ac-
cording to standard departmental guidelines. None of
the patients receive keratinocyte growth factor (KGF)
for mucositis prophylaxis.Renal Failure
Renal failure was defined as serum creatinine
$2 mg/dL sustained for .1 month before the start
of preparative regimen [8,9,13,14]. The glomerular
filtration rate (GFR) was derived from the serum cre-
atinine values by the Cockcroft Gault formula. This
formula is considered a Level A recommendation for
accurate measurement of renal function [15]. The
data on patient’s sex, height, and weight at the time
of transplant were taken into consideration for baseline
GFR calculations. GFRwas calculated for each patient
at baseline (pretransplant) and at 3, 6, 9, and 12months
after auto-HSCT. Based on the baseline GFR at the
initial diagnosis the patients were subgrouped as
chronic kidney disease (CKD) stages 3 to 5 (Table 1)
according to the National Kidney Foundation’s Kid-
ney Disease Outcomes Quality Initiative (K/DOQI
initiative) [16].
Improvement in renal function was defined as an
increase in GFR by $25% compared to the baseline.
Patients were also grouped according to dialysis
dependency status.Response Criteria
The european group for Blood and Marrow
Transplantation (EBMT) response criteria were used
to define complete remission (CR), partial response
(PR), and relapse [17]. CR was defined as the absence
of original monoclonal protein in urine and serum by
immunofixation, \5% plasma cells in marrow aspi-
rate, and no increase in the size or number of lytic
bony lesions. Progressive disease (PD) was defined as
1 of the following: (1).25% increase in serum or urine
monoclonal protein, or plasma cells in the bone mar-
row, or (2) increase in the size or number of lytic
bony lesions. All responses were in reference to auto-
HSCT.
Table 2. Characteristics of 46 Patients Undergoing Auto-
HSCTWhile in Renal Failure
Characteristics Number (%)
Males 31 (67%)
Median age (range) 56 (29-72 years)
Durie-Salmon stage III 27 (56%)
Dialysis dependence 10 (22%)*
Light chain-only disease 25 (54%)
Albumin <4 g/L 29 (63%)
LDH >618 U/L 17 (37%)
b2M > 8 mg/L 23 (50%)
Median prior chemotherapies (range) 3 (0-6)
Median CD34 cells 106/kg (range) 4.47 (1.4-9.7)
Cytogenesis
Abnormal 10 (21%)
Normal 27 (56%)
Unknown 9 (23%)
Response to prior chemotherapy
Partial response 27(58%)
Minimal response 8 (18%)
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The primary endpoints were overall survival (OS)
and NRM at day 1100 and 1 year after transplanta-
tion. Outcomes were estimated starting on the day of
auto-HSCT. NRM was defined as death occurring in
the absence of progression or relapse of malignancy,
and was estimated using the cumulative incidence
method considering disease progression as a compet-
ing risk. Actuarial OS and progression-free survival
(PFS) were estimated by the method of Kaplan-Meier.
Outcomes according to pretransplantation character-
istics were compared on univariate analysis using the
Cox’s proportional hazards model. Multivariate analy-
sis was not possible because of sample size consider-
ations. All p values presented are 2-sided. Statistical
analyses were carried out using Stata 8.0.Nonresponder 8 (18%)
Progressive 2 (4%)
Unknown 1 (2%)
Melphalan dose
180 mg/m2 9 (29%)
200 mg/m2 33 (65%)
140 mg/m2 4 (6%)
Time from diagnosis to transplant
#12 months 28 (61%)
>12 months 18 (39%)
Mobilization regimen
G-CSF only 36 (78%)
Chemo + G-CSF 10 (22%)
LDH indicates lactic dehydrogenase; b2M, beta 2 microglobulin; G-CSF,
granulocyte colony stimulating factor; auto-HSCT, autologous hemato-
poietic stem cell transplantation.
*Two patients were on peritoneal dialysis.RESULTS
Patients
Table 2 summarizes the characteristics of the 46
patients included in this analysis. The median age
was 54 years (range: 29-72). Median number of prior
treatments was 3 (range: 0-6). Ten patients (21%)
were dialysis-dependent at the time of auto-HSCT, 8
on hemodialysis and 2 on peritoneal dialysis. Thirty-
three patients received Mel 200 mg/m2, whereas 13
patients received a Mel dose of either 140 or 180
mg/m2. There was no association between M dose
and the following: severity of renal failure/dialysis de-
pendence (P 5.57); or age .65 years (P 5.31).
Stem Cell Mobilization and Engraftment
PBSCs were mobilized with G-CSF alone in 36
cases and with chemotherapy 1 G-CSF in 10 cases.
Ten (21%) patients with high tumor burden received
chemotherapy1G-CSF 10 mg/kg/day, with modified
CVADregimen (Cy, vincristine, adriamycin, and dexa-
methasone) to achieve optimal cytoreduction. An ade-
quate number of CD341 cells (.2  106/kg ) were
collected from all 46 patients. Median times to neutro-
phil (ANC $0.5  109/L) and platelet engraftment
(.50  109/L) were 10 (range: 9-18) and 12 (range:
8-81) days, respectively.
Treatment-Related Toxicity
Two patients died of nonrelapse within 100 days
(100-day NRM: 4%) and a total of 3 patients had
died at 1 year (1 year NRM: 7%). None of the patients
receiving Mel 200 mg/m2 died in the first 100 days
(100-day NRM 0%) versus 2 of 13 in the who received
either 140 or 180 mg/m2 (P5 .07). One patient died of
sepsis/multiorgan failure, and 1 from pulmonary fail-
ure/idiopathic pneumonia syndrome. The cause of
death was not known in 1 patient, who died at anoutside institution. Grade II/IV nonhematologic
toxicity was reported in 18 (39%) patients. None of
the 10 dialysis-dependent patients died of nonrelapse
causes. There was no significant difference in grade
II-IV toxicity between dialysis-dependent and dialysis
independent patients (13/36 versus 5/10, P 5 .4). The
adverse events included cardiac arrythmias, pulmonary
edema, hyperbilirubinemia, nausea, vomiting, and
diarrhea. The most common toxicities were diarrhea,
nausea, vomiting, and dysphagia. Severe mucositis
(grade .3) was seen in only 6% of patients.Clinical Response and Survival
Median follow-up among surviving patients was 34
months (range: 5-81). CR and PRwere seen in 9 (22%)
and 22 (53%) of the 41 evaluable patients, respectively,
with an overall response rate (ORR) of 75% from the
time of auto-HSCT. As of last follow-up, 16 patients
have died. Median PFS was 25 months, and median
OS has not been reached. Figure 1. Kaplan-Meier
estimates of 3-year PFS and OS were 36% and 64%,
respectively. Thirty patients (62.5%) are still alive after
a median follow-up of 34 months, and 18 patients
(39%) are alive and progression free.
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Fifteen patients (32%) experienced a sustained im-
provement in renal function, defined as an increase in
GFR by 25% above baseline on 2 separate occasions, 3
months apart. There was a downstaging of renal failure
in 10 patients (21%). However, none of the 10 dialysis-
dependent patients were able to attain independence
from dialysis. The OS was not affected by the stage
of CKD (P 5 .9).
Prognostic Factors
Serum creatinine prior to auto-HSCT, disease
status at auto-HSCT, dialysis-dependence, stage of
chronic renal disease, Mel dose, or serum lactate dehy-
drogenase (LDH) did not emerge as significant predic-
tors of PFS or OS. This retrospective analysis,
however, was not powered to detect the impact of
various prognostic factors in a small and heteroge-
neous population.DISCUSSION
Renal failure is a well-known complication of MM
and is considered a marker for poor prognosis [5]. Sev-
eral randomized trials support the role of HDT and
auto-HSCT as standard treatment for MM because
of its association with a higher CR rate, and longer
event-free survival (EFS) and OS [6,7]. Patients with
concomitant renal failure are generally excluded from
this treatment because of an increased risk ofmorbidity
and mortality. These morbidities include infections,
encephalopathy, and mucositis. Some studies have re-
ported a 5% to 29% risk of NRM in this patient popu-
lation [18]. Badros et al. [9] reported an early NRM of
5%withMel 140mg/m2, and 7%withMel 200mg/m2.
A report from the same institution by Lee et al. [14]
reported a 6-monthNRMof 11% in 59 dialysis-depen-
dent patients. Three other studies reported anNRMof
17%,18.5%, and29% [8,10,19].Our study, in compar-
ison, reports an NRM of only 4% at 100 days, and 6%
at 1-year post-HSCT. In our report, only 1 of 33
patients receiving Mel 200 mg/m2 died of nonrelapse
causes, which was not different from the NRM seen
at lower Mel doses of 140 mg/m2 (1 of 4) and 180
mg/m2 (1 of 9). Notably, there was no NRM in 10
dialysis-dependent patients after a 1-year follow-up.
This improvement in NRMmay be because of patient
selection because these patients other than renal failure
were acceptable candidates for HDT with adequate
vital organ function. An improvement in supportive
care measures including antimicrobial and mucositis
prophylaxis may also have contributed to low treat-
ment-related mortality (TRM).
Auto-HSCT in patients withMM and renal failure
has been associated with partial or complete recovery
of renal function, even in dialysis-dependent patients[8-10,14]. Lee et al. [14] reported an improvement in
renal function manifested as dialysis independence in
13 of the 54 evaluable patients (24%). In contrast,
Badros et al. [9] reported a partial recovery of renal
function in only 2 of the 38 dialysis-dependent pa-
tients. In our series, 15 of 46 (32%) experienced a sus-
tained and quantifiable improvement in renal function.
There was downstaging of renal failure in 10 patients
(21%). Furthermore, 3 of the 10 dialysis-requiring pa-
tients also achieved an improvement in renal function,
although none of them achieved independence from
dialysis. That may be related to irreversible renal dam-
age or the duration of renal failure. Renal failure or di-
alysis did not interfere with PBSC mobilization or
collection in this cohort of patients, and an average
of .4  106 CD341 cells/kg were collected. The
time to neutrophil and platelet engraftment was com-
parable to patients with normal renal function [20].
Significant cardiac, pulmonary, andneurologic tox-
icity have been reported with a Mel dose of 200 mg/m2
[9], and a reduced dose, 140mg/m2,was recommended.
In this report, even with aMel dose of 200mg/m2 in 33
of 46 patients, grade II/IV nonhematologic toxicity was
seen in 18 (39%) patients, with most of adverse events
being mild and reversible. Some of the common events
were diarrhea, nausea, vomiting, and dysphagia. This
lower rate of adverse events may be related to improve-
ments in supportive care, although suboptimal docu-
mentation of adverse events cannot be ruled out
because of retrospective nature of this analysis. We
compared the outcome of this analysis with the out-
come of 48 MM patients who received Mel 200 mg/
m2 and had serum creatinine of\2mg andwere treated
between 2004 and 2006. Although not a direct compar-
ison, the outcome did not appear to be significantly dif-
ferent between the 2 groups.The 100-dayNRM,ORR,
3-year PFS, and OS in the group with normal function
were 0%, 85%, 25%, and 35, respectively. In compari-
son, the 100-dayNRM,ORR, 3-yearPFS, andOSwere
0%, 85%, 36%, and 64%, respectively, in the current
analysis [21].
Our study had the inherent limitations of a retro-
spective analysis, including the variability in Mel dose
and disease status and a relatively small number of pa-
tients. It would be helpful to develop a standardized
regimen tailored for patients with impaired renal func-
tion. Future prospective clinical trials may address the
optimal Mel dose, impact of renal failure onMel phar-
macokinetics, role of newer antimyeloma agents in pre-
parative regimens, and the timing of auto-HSCT in
patients with MM and concomitant renal failure.
In summary, auto-HSCT may be offered to pa-
tients with MM and renal failure, with acceptable tox-
icity andNRM, and a significant improvement in renal
function in one-third of these patients. In this analysis,
aMel dose of 200mg/m2was not associated with an in-
crease in toxicity or NRM.
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Figure 1. (A) Kaplan-Meier estimate of progression-free survival in 46
patients receiving auto-HSCT forMM and renal failure. (B) Kaplan-Meier
estimate of overall survival in 46 patients receiving auto-HSCT for MM
and renal failure.
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